ORAMED PHARMACEUTICALS INC.
Oramed Pharmaceuticals, established in 2006, developed a proprietary platform for oral delivery of drugs typically administered by injection. Their flagship product is oral insulin (ORMD-0801) for type 2 diabetes, with ongoing clinical trials under the FDA, and ORMD-0901, an oral GLP-1 analog. Oramed aims to improve lives worldwide by transforming injectable treatments into oral therapies.
Offizielles Register
KI-Qualitätsanalyse
Vertrauensscore-Details
Schnellzugriff
Website-Highlights
🌟 Ähnliche vertrauenswürdige Unternehmen
KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals is dedicated to advancing science to improve the lives of individuals, with an initial focus on hereditary angioedema (HAE). They are developing orally-delivered small molecule medicines to transform the HAE treatment landscape and address unmet patient needs. Their goal is to make a meaningful difference for people living with HAE by offering new possibilities for disease management. KalVista's lead product is an oral on-demand treatment for HAE.
Harmony Biosciences Holdings, Inc.
Harmony Biosciences is a pharmaceutical company focused on developing and delivering innovative therapies for rare neurological diseases. They specialize in treatments for sleep/wake disorders, neurobehavioral conditions, and rare epilepsies. With a commitment to empathy and innovation, they aim to improve the lives of patients by addressing unmet medical needs and advancing patient-kind through novel treatments.
Novo Nordisk A/S
Novo Nordisk is a global pharmaceutical company focused on treating diabetes, obesity, and other serious chronic diseases. They offer innovative medicines and delivery systems, holding a leading position in diabetes care. The company is committed to sustainable development and patient access.